image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Updates

CVS Group

November 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • CVS
  • Price:
  • 1602p
CVS had already issued a trading update covering the full year so its results contained no surprises and were “in line with expectations”. Adjusted EBITDA did slightly beat consensus coming in at £121.4m (versus £115m) with EBITDA margin of 20%. Net debt rose from £36m to £74m reflecting various acquisitions including 4 independent practices in Australia. Staffing remains the biggest challenge in the industry but CVS managed to increase its average number of vets employed by 6.5%. Meanwhile, the Healthy Pet Club grew number of members by 4% to 494,000. The shares have fallen due to uncertainty caused by the Competition and Markets Authority review into the sector. Await developments. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

CVS Group (January 2024)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X